Fundz

cbdMD

Charlotte, North Carolina, United States · Dietary Supplements, Health Care, Other

cbdMD, INC. is a reputable company specializing in CBD products. It offers a range of health and wellness products derived from hemp. The company is dedicated to quality and transparency in its offerings. Based in Charlotte, North Carolina, it operates under the NYSE American exchange.

Key facts

Headquarters
Charlotte, North Carolina, United States
Employees
Unknown
Industries
Dietary Supplements, Health Care, Other
Status
Public (YCBD)
Website
cbdmd.com
LinkedIn
Company page

Recent activity at cbdMD

  • : cbdMD to acquire Twinlab for wellness expansion
  • : cbdMD Appoints Wade Brown as Chief Marketing Officer
  • : cbdMD, Inc. launches a new clinical healthcare channel aimed at supporting federal hemp-derived CBD access in Medicare.
  • : SEC 8-K (2.01): On October 30, 2026, cbdMD, Inc. completed the acquisition of assets from Twinlab Consolidated Holdings, Inc. and its subsidiaries through an Asset Purchase Agreement. The transaction involved the acquisition of significant assets used in Twinlab's business of marketing and distributing nutritional supplements, including intellectual property, contracts, permits, inventory, accounts receivable, and shares of certain subsidiaries. The total consideration for the acquisition included the assumption of senior secured debt, issuance of 2,229,805 shares of common stock valued at $1.00 per share to the Secured Creditor, and additional shares to maintain specified ownership percentages, indicating a strategic expansion for cbdMD, Inc. The deal was executed following court approval and was aimed at enhancing the Company's market position in the nutritional supplement sector.
  • : SEC 8-K (1.01): On September 1, 2026, cbdMD, Inc. entered into a Material Definitive Agreement, specifically an Asset Purchase Agreement with To Be Brands, LLC, Twinlab Consolidated Holdings, Inc., its subsidiaries, and their assignee Philip J. Von Kahle. The agreement allows cbdMD to acquire significant assets including stock in Twinlab subsidiaries, intellectual property, inventory, and receivables. This strategic acquisition is a crucial step for cbdMD to enhance its operational capabilities and expand its market presence. Financial details regarding the acquisition amount are not disclosed in the filing, but it aligns with cbdMD's plans for growth and consolidation. The agreement is set to enhance cbdMD's portfolio and strengthen its competitive position in the market.
  • : SEC 8-K (1.01): On May 20, 2026, cbdMD, Inc. entered into a Third Amendment to Lease, extending their Warehouse Lease located at 2101 Westinghouse Boulevard, Charlotte, NC. The lease extension will last 62 months, starting October 1, 2026, and finishing on November 30, 2031, for a space reduced to 40,000 square feet. The first year of the renewal term will have a lower monthly rent of $38,000, contributing to an annual gross rent expense reduction of approximately $450,000 and a net rent expense reduction of $100,000 to $120,000 annually. This strategic decision aligns with the company's current operational needs and is seen as beneficial for reducing operating expenses.
  • : SEC 8-K (8.01): On April 14, 2026, cbdMD, Inc. issued 1,572 restricted stock units (RSUs) to each independent director and the non-management employee director as compensation for their services. This compensation is for the term beginning March 31, 2026, and the RSUs will vest quarterly starting June 30, 2026. Additionally, the board approved annual fees for independent directors, including a monthly cash retainer of $35,000 and varying amounts for committee chairs and members. These RSUs' value is based on the NYSE closing price on the issuance date, April 14, 2026, which indicates the board's commitment to aligning compensation with shareholder interests.
  • : SEC 8-K (5.02): On March 30, 2026, cbdMD, Inc. experienced a significant corporate event where the shareholders approved the 2025 Equity Compensation Plan, which reserves 891,316 shares of common stock for employee incentives including stock options and awards. This plan features an ‘evergreen formula’ that will increase the share availability annually by 2% of outstanding shares, up to 300,000 shares. Additionally, as part of an Executive Employment Agreement effective November 28, 2025, CEO T. Ronan Kennedy was granted a restricted stock award contingent on this approval, enabling him to receive 445,000 shares once the plan was sanctioned. The implementation of this plan will impact future compensatory arrangements, supporting the company’s employee retention strategies and aligning executives' interests with shareholder value. The details of the proposal and its implications were documented in the definitive proxy statement filed earlier in February 2026.
  • : SEC 8-K (1.01): On January 12, 2026, cbdMD, Inc. entered into a definitive Asset Purchase Agreement with Gaia Botanicals, LLC, acquiring substantially all of Gaia's assets, including its brand, online marketplace, trademarks, and inventory. The acquisition was valued at 425,000 shares of restricted common stock, with an additional earnout of up to 525,000 shares contingent on future performance. The shares are subject to a 180-day lock-up agreement, and the deal was executed under the exemption provisions of the Securities Act. This strategic move enables cbdMD to enhance its product offerings and market presence in the CBD sector.
  • : SEC 8-K (1.01): On January 12, 2026, cbdMD, Inc. entered into a Material Definitive Agreement with Gaia Botanicals, LLC for the acquisition of substantially all of Gaia's assets. This includes Gaia's brand name, online CBD marketplace 'https://www.bluebirdbotanicals.com/', related trademarks, and certain inventory and liabilities. The acquisition was conducted for 425,000 shares of cbdMD's restricted common stock at closing, along with the potential for an earnout amount of up to $52 million depending on future performance. This strategic move aims to enhance cbdMD's market presence and product offerings in the CBD industry.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

cbdMD funding history

DateRoundAmount
Jun 2015VentureUndisclosed

Leadership

  • Alyssa Head, Director of Marketing
  • Anthony Shriver, Director
  • Erik Sterling, Director
  • W Anderson, Executive Officer, Director
  • Martin Sumichrast, Executive Officer, Director
  • Wade Brown, Vice President Marketing
  • Joe Baghadjian, VP of Wholesale

Verified email and direct lines for cbdMD’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

cbdMD in the news

Companies similar to cbdMD

About cbdMD: questions and answers

What does cbdMD do?

cbdMD, INC. is a reputable company specializing in CBD products. It offers a range of health and wellness products derived from hemp. The company is dedicated to quality and transparency in its offerings. Based in Charlotte, North Carolina, it operates under the NYSE American exchange.

Where is cbdMD headquartered?

cbdMD is headquartered in Charlotte, North Carolina, United States.

Has cbdMD raised funding?

Yes. Fundz has recorded 1 funding event for cbdMD. The most recent, Undisclosed, was in Jun 2015.

Who leads cbdMD?

Wade Brown is a Vice President Marketing at cbdMD.

What is the latest news on cbdMD?

On Sep 2, 2026, cbdMD to acquire Twinlab for wellness expansion

Is cbdMD a public company?

Yes. cbdMD is publicly traded under the ticker YCBD.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches cbdMD across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.